NCT07243262Recruiting
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)
Source: ClinicalTrials.gov · Last updated 9 Jul 2026
Brief summary (registry, in English)
The investigators are developing a non-invasive breath test to help us detect pancreatic cancer earlier. The test detects small molecules called volatile organic compounds that are made by pancreatic cancers. Pancreatic cancer is a rare disease but patients are often diagnosed at a late stage because their symptoms are the same as those of many common illnesses. This makes it hard for doctors to know which patients need to be tested for pancreatic cancer. If the investigators find pancreatic cancer at a late stage, it reduces the number of treatment choices for patients. Our test could be offered to patients who are experiencing vague symptoms, which might be caused either by pancreatic cancer or a common illness. This test could help doctors to identify which of those patients may have pancreatic cancer, and ensure they get referred for specialised pancreatic cancer tests. The investigators hope that this will allow us to diagnose pancreatic cancer earlier, increasing treatment choices for patients and improving survival from pancreatic cancer. The investigators have previously conducted a study (VAPOR1) which collected breath samples from people with and without pancreatic cancer. When the investigators analysed these samples, they found that there is a difference in the volatile organic compounds breathed out by people who have pancreatic cancer compared to those that do not. The investigators used these 'markers' to develop a breath test to diagnose pancreatic cancer. In VAPOR2, the investigators will study our breath test in a much larger group of patients who have been referred for further investigations for potential underlying pancreatic cancer to see how accurately it can pick up the small percentage of people who have pancreatic cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 6079 (estimated)
- First submitted
- 17 Nov 2025
- Start date
- 21 Oct 2025
- Primary completion date
- 1 Aug 2028
- Lead sponsor
- Imperial College London
- Diseases
- Pancreatic cancer
- NCT number
- NCT07243262
What you commit to
- Study type: Observational
- Planned participants: 6079
- From 21 Oct 2025 to the primary completion date, 1 Aug 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous pancreatic resection
Other illness
- History of another cancer (other than non-melanoma skin cancers) within three years
Other
- Pregnant participants (pregnancy status to be confirmed verbally with the participant)
- Participants with co-morbidities preventing breath collection
- Unable or unwilling to provide informed consent
Who the study is looking for
- Adult participants ≥ 18 years old
- Referral from primary care according to the urgent suspected cancer referral guidelines for potential underlying pancreatic cancer, or referral directly to a pancreatic cancer multidisciplinary team meeting
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Imperial College Healthcare NHS Trust Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.